


Proactive Lung Cancer Detection

Made Simple

Now available at select health systems,
ProVue Lung is a novel blood test powered by proteomics, to enhance lung cancer detection.



ProVue Lung Improves Lung Cancer Detection

ProVue Lung is a novel blood-based Laboratory Developed Test (LDT) designed to improve detection of lung cancer at its earliest, most treatable stages. With just a simple blood draw, ProVue Lung offers a convenient, scalable way to enhance existing screening programs and increase patient adherence.



Lung Cancer Screening: a Significant Unmet Need

Lung cancer is the leading cause of cancer deaths worldwide, responsible for nearly one in five cancer-related deaths.¹ In the U.S., more than 14 million people are considered high risk and recommended for annual screening with low-dose CT (LDCT), yet **fewer than 16% of high-risk individuals undergo screening.**¹

ProVue Lung is a simple blood-based test designed to enhance existing screening programs and improve patient adherence. By enabling early-stage detection—when lung cancer is most treatable—this test offers a powerful tool to help improve outcomes for patients at risk for this deadly disease.

Early. Effective. Evidence-Based.

ProVue Lung has been shown to identify many lung cancers at Stage I, when treatment is most effective. Designed for high-risk adults 50 years of age and older with a 20+ pack-year smoking history, the test uses a simple blood draw to reduce barriers to screening and integrates easily into existing workflows—helping more patients get the care they need.



Identifies many lung cancers, including at Stage I, when treatment is most effective.



Convenient blood draw reduces existing barriers to screening.




Designed for high-risk adults 50 years of age and older with a 20+ pack-year smoking history.



Proteomics at the Core of Early Lung Cancer Detection

ProVue Lung is a proteomics test which was developed through PrognomiQ's proprietary multi-omics platform to uncover unique molecular signatures of disease. This approach enables high-performance identification of disease at its earliest stages.



Why ProVue

- Addresses a major unmet medical need, **increasing early detection rates** for lung cancer.
- **Convenient blood draw**, lowering barriers to adherence.
- High sensitivity for early-stage disease, helping **identify cancers when treatment is most effective**.
- **Backed by rigorous science and innovation**, transforming the detection and treatment of lung cancer by harnessing the power of proteomics data.

Strong Clinical Performance in Lung Cancer Detection, including for Early Stage

ProVue Lung was validated in multiple prospective, case-control studies, including in a separate independent cohort to assess Stage I sensitivity performance²

>99.8%

NPV

85%

SENSITIVITY FOR
ALL-STAGES OF
LUNG CANCER

55%

SPECIFICITY

80%

SENSITIVITY FOR
STAGE I LUNG
CANCER



Now Available at Select Health Systems

ProVue Lung is initially being launched as a LDT with leading health systems committed to advancing early detection. This first step will generate real-world evidence to facilitate future development.

Contact Information

Contact PrognomiQ to learn how ProVue Lung can enhance lung cancer screening in your health system.

Phone: 650-750-2450

Email: provuelung.info@prognomiq.com

Website: prognomiq.com

Indications for Use: ProVue Lung is intended as an adjunct assessment tool for adults deemed at high risk of lung cancer and consistent with lung cancer screening guidelines by USPSTF³, ACS⁴, and/or NCCN⁵.

Laboratory Information: The ProVue Lung test is a laboratory developed test (LDT). This test was developed by PrognomiQ. It has not been cleared nor approved by the US Food and Drug Association (FDA). The laboratory is regulated under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity clinical tests. The test is used for clinical purposes. It should not be regarded as investigational or for research.

We are proud to be a CLIA-certified and CAP-accredited laboratory

- ☑ Delivering optimal patient care
- ☑ Evolving with innovation in laboratory medicine



References: 1. American Lung Association. Lung cancer key findings. Accessed November 13, 2024. <https://www.lung.org/research/state-of-lung-cancer/key-findings>
2. Unpublished data on file; manuscript under preparation 3. U. S. Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962-970. doi:10.1001/jama.2021.1117 4. Wolf AMD, Oeffinger KC, Shih TY, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2024;74(1):50-81. doi:10.3322/caac.21811 5. NCCN Guidelines® Insights: lung cancer screening, version 1.2026.